New drug cocktail targets tough lung cancer

NCT ID NCT07669779

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This phase 2 trial tests a new drug called AK146D1, given together with other cancer drugs, in 348 people with advanced non-small cell lung cancer that cannot be surgically removed. The study aims to see if the combination is safe and can shrink tumors. Participants will receive the drugs by injection or infusion, and researchers will monitor side effects and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AK146D1 (a bispecific antibody-drug conjugate targeting Trop2 and Nectin4) combined with AK112 (a bispecific antibody targeting PD-1 and VEGF) or other anticancer drugs
What this could lead to
If successful, this could provide a new treatment option for advanced non-small cell lung cancer that has not responded to other therapies.
What could go wrong
This is an early phase 2 trial, so the combination may not prove effective or safe enough for wider use. Side effects from the drug combination are possible and being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • SunYat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.